Journey Medical (DERM) has a profit margin of -8.95%, below the sector sector average of 13.09%.
Get informed when a big investor buys or sells
+ FollowAs of Jun 2026
Trailing 12 months ending Jun 2026
The latest profit margin for DERM is -8.95% as of June 2026. That compares with -15.49% in the prior-year period — up 42.2% year over year. That is below the sector sector average of 13.09%. Investors often review this figure alongside Journey Medical's historical trend and sector peers before judging valuation or financial health.
Over the past year, DERM's profit margin moved from -15.49% to -8.95% — a 42.2% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Journey Medical's valuation or profitability profile.
Against its sector companies, DERM currently prints -8.95% for profit margin, while the sector average sits near 13.09%. That is roughly 168.4% below the sector mean. Large gaps often invite a closer look at Journey Medical's growth, margins, and balance sheet.
Profit Margin shows how effectively Journey Medical converts resources into returns. At -8.95%, DERM may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -15.49% in the prior-year period — up 42.2% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting DERM's profit margin (-8.95%), review year-over-year change from -15.49%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.